medRxiv (2023). 10.1101/2023.04.11.23288400.
The impact of alternative delivery strategies for novel tuberculosis vaccines in low-income and middle-income countries: a modelling study.
The Lancet. Global health, (2023).11 4 10.1016/s2214-109x(23)00045-1.
Clinical trials of tuberculosis vaccines in the era of increased access to preventive antibiotic treatment.
The Lancet. Respiratory medicine, (2023).11 4 10.1016/s2213-2600(23)00084-x.
Demonstrating multi-country calibration of a tuberculosis model using new history matching and emulation package - hmer.
Epidemics, (2023).43, 10.1016/j.epidem.2023.100678.
New tuberculosis vaccines in India: Modelling the potential health and economic impacts of adolescent/adult vaccination with M72/AS01 E and BCG-revaccination.
medRxiv (2023). 10.1101/2023.02.24.23286406.
Cost-effectiveness of tuberculosis infection prevention and control interventions in South African clinics: a model-based economic evaluation informed by complexity science methods.
BMJ Global Health, (2023).8 2 10.1136/bmjgh-2022-010306.
The cost and cost-effectiveness of novel tuberculosis vaccines in low- and middle-income countries: A modeling study.
PLOS Medicine, (2023).20 1 10.1371/journal.pmed.1004155.
Updating age-specific contact structures to match evolving demography in a dynamic mathematical model of tuberculosis vaccination.
PLoS Computational Biology, (2022).18 4 10.1371/journal.pcbi.1010002.
The impact of alternative delivery strategies for novel tuberculosis vaccines in low- and middle-income countries: a modelling study.
medRxiv (2022). 10.1101/2022.04.16.22273762.
Dosing interval strategies for two-dose COVID-19 vaccination in 13 middle-income countries of Europe: Health impact modelling and benefit-risk analysis.
The Lancet Regional Health - Europe, (2022).17, 10.1016/j.lanepe.2022.100381.